🇪🇺 sofosbubir/velpatasvir/voxilaprevir in European Union

EMA authorised sofosbubir/velpatasvir/voxilaprevir on 26 July 2017

Marketing authorisation

EMA — authorised 26 July 2017

  • Application: EMEA/H/C/004350
  • Marketing authorisation holder: Gilead Sciences Ireland UC
  • Local brand name: Vosevi
  • Indication: Vosevi is indicated for the treatment of chronic hepatitis C virus (HCV) infection in patients aged 12 years and older and weighing at least 30 kg. (see sections 4.2, 4.4 and 5.1).
  • Status: approved

Read official source →

Other Infectious Disease / Virology approved in European Union

Frequently asked questions

Is sofosbubir/velpatasvir/voxilaprevir approved in European Union?

Yes. EMA authorised it on 26 July 2017.

Who is the marketing authorisation holder for sofosbubir/velpatasvir/voxilaprevir in European Union?

Gilead Sciences Ireland UC holds the EU marketing authorisation.